AMEX · VTAK

Catheter Precision, Inc.

$0.29 +$0.03 (+10.39%) 1D After hours

Key Metrics

$948.21K
Market cap
0.40×
P/E · TTM
$289.00K
Revenue · TTM
$2.36M
Net income
EPS · TTM $3.98
Dividend yield
Free cash flow
Beta · 1Y 0.91
EBITDA · TTM
Gross margin 89.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 87%.

    Peak close $2.08 on Jan 29; trough close $0.26 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -87%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +92.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Apr 9
    The stock moved +40.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$948.21K
Enterprise value
Shares outstanding3.6M
52-wk range$0.23 – $4.31
Avg volume · 20D1.0M
Net cash
Book value / share$16.11
IndustrySurgical & Medical Instruments & Apparatus
ExchangeAMEX
About Catheter Precision, Inc.
IPO dateSep 27, 2018
Employees17

Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E0.40
P/S3.28
P/FCF
EV/EBITDA
EV/Sales
Graham №$37.99

Profitability

Gross 89.3%
Operating 1,004.8%
Net 818.0%
FCF
ROE / ROIC 24.7% · —

Financial Health

Current ratio0.06
Quick ratio0.06
Debt / equity
Debt / EBITDA
Net cash
Working capital−$18.49M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-12.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$37.99 vs $0.29
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings